For dominant disorders that occur mostly through inherited rather than de novo mutations (e.g., BRCA1/2 and HNPCC mutations that lead to hereditary nonpolyposis colon cancer), such an approach would dramatically reduce the frequency of these disorders in a single generation and for all generations to come except for new mutations. The gene discussed is BRCA1; the disease is hereditary nonpolyposis colon cancer.